Ctre Hospitalier Intercomm R Ballanger
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
The department is investigating whether adding corticosteroids to standard antibiotic therapy can improve recovery in adult patients with septic arthritis, a serious bacterial joint infection.
- Adjunct corticosteroid use in septic arthritis
- Effect on joint function at 24 weeks
- Interaction with antibiotic regimens
- Safety and adverse‑event monitoring
Ctre Hospitalier Intercomm R Ballanger currently supports four trials with six investigators, contributing to advances in infectious disease care.
Cardiovascular Diseases
A key focus is the management of post‑resuscitation syndrome in adults who have experienced cardiac arrest, testing a combination of vasopressin and hydrocortisone to boost survival and neurological recovery.
- Vasopressin plus hydrocortisone protocol
- 30‑day survival outcomes
- Neurological function assessment
- Hemodynamic stabilization strategies
The site’s cardiovascular research aligns with its broader mission to improve acute care outcomes across Europe.
Hemic and Lymphatic Diseases
Researchers are evaluating the oral kinase inhibitor itacitinib for adult patients with non‑severe Hemophagocytic Lymphohistiocytosis (HLH), aiming to increase complete and partial response rates.
- Itacitinib efficacy in HLH
- Day‑15 response assessment
- Clinical and biological symptom tracking
- Safety and tolerability profile
This trial adds to the limited therapeutic options for HLH and reflects the center’s commitment to rare hematologic conditions.
Immune System Diseases
The team is conducting a study on sarcoidosis, an immune‑mediated lung disorder, to see if hydroxychloroquine combined with low‑dose corticosteroids can maintain or improve respiratory function over six months.
- Hydroxychloroquine plus low‑dose steroids
- Pulmonary function outcomes
- Non‑inferiority comparison design
- Long‑term safety monitoring
By addressing an autoimmune lung disease, the site broadens its impact on both respiratory and systemic immune research.
Respiratory Tract Diseases
In the respiratory arena, the hospital evaluates therapies that target lung involvement in sarcoidosis, focusing on functional improvement and quality of life for patients receiving novel anti‑inflammatory regimens.
- Assessment of lung function trends
- Patient‑reported outcome measures
- Comparative effectiveness of anti‑inflammatory agents
- Monitoring of adverse respiratory events
These efforts complement the institution’s broader commitment to advancing care for chronic respiratory conditions across France.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 9 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ctre Hospitalier Intercomm R Ballanger
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Prednisone Adjunct to Antibiotic Therapy in Adults with Septic Arthritis: A Randomized Double-Blind Controlled Trial | Assistance Publique Hopitaux De Paris | Phase III | Recruiting | Jun 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisone | 2 | Unknown | 2024-10-28 | 2026-06-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.